Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Altria is the dominant U.S. tobacco company controlling ~42% of the domestic cigarette market through its Marlboro brand, generating $20B+ in annual revenue from combustible cigarettes (85%+ of revenue), oral tobacco products (Cope/Skoal), and on! nicotine pouches. The company operates a declining but highly profitable business with 86.6% gross margins and $9.1B in free cash flow, returning capital to shareholders through a 7.5%+ dividend yield while managing secular volume declines of 8-10% annually.
Altria generates cash through oligopolistic pricing power in a declining market. With Marlboro commanding 42%+ market share and limited competition (Reynolds American/ITG control most remaining share), the company raises prices 8-10% annually to offset 8-10% volume declines, maintaining revenue stability. Gross margins of 86.6% reflect minimal COGS (tobacco leaf, paper, filters) versus premium pricing. The business model relies on addictive products with inelastic demand among existing smokers, regulatory barriers preventing new entrants, and Master Settlement Agreement payments creating fixed cost structures that favor scale players. Operating margins of 74.8% demonstrate extreme operating leverage once fixed MSA payments and overhead are covered.
Cigarette volume decline rates - market watches for acceleration beyond 8-10% baseline indicating consumer trade-down or quitting acceleration
Pricing realization - ability to take 8-10% annual price increases without elasticity breaking (revenue management execution)
Regulatory developments - FDA menthol ban proposals, nicotine reduction standards, flavor restrictions on oral/pouch products
Smoke-free portfolio momentum - on! nicotine pouch volume growth, retail distribution gains, and path to profitability
Capital allocation decisions - dividend sustainability at 7.5%+ yield, share buyback capacity, M&A speculation (cannabis, international expansion)
Secular cigarette volume decline acceleration beyond 8-10% baseline as younger cohorts never initiate smoking and older smokers quit or die
FDA regulatory action including menthol cigarette ban (35% of industry volumes), nicotine reduction mandates, or flavor restrictions on oral/pouch products that could disrupt pricing power or accelerate volume declines
Litigation risk from individual and class-action lawsuits despite MSA protections, with potential for punitive damages in state courts
Smoke-free product transition risk - on! nicotine pouches face competition from Zyn (Philip Morris/Swedish Match) with 70%+ category share, and Altria lacks proven innovation capability after JUUL investment write-off
Reynolds American (British American Tobacco) competitive pricing or innovation in cigarettes and oral tobacco, particularly Vuse e-vapor leadership
Zyn nicotine pouch dominance (Swedish Match/Philip Morris) with 70%+ market share versus on!'s 5-6% share, limiting Altria's smoke-free growth runway
Illicit trade and counterfeit products capturing 5-10% of market during economic stress, eroding tax base and legitimate volumes
Negative equity position (ROE of -215.2%) from accumulated losses on JUUL investment write-down ($12B+ impairment) and Anheuser-Busch InBev stake mark-to-market losses, though operationally irrelevant given cash generation
Dividend sustainability risk if volume declines accelerate beyond pricing ability - current 80%+ payout ratio leaves limited buffer, though $9.1B FCF provides 2.5x coverage at current $7B annual dividend
Pension and OPEB obligations for legacy workforce, though well-funded relative to peers
low - Cigarette consumption is highly inelastic due to addiction, with minimal correlation to GDP or employment. During recessions, consumers may trade down from premium to discount brands (margin pressure) but rarely quit due to economic factors. Oral tobacco similarly demonstrates recession-resistant demand. The 34.5% net margin and $9.1B FCF reflect business model insulation from economic cycles.
Rising rates create moderate valuation pressure as high-dividend tobacco stocks compete with risk-free yields - the 7.5%+ dividend yield becomes less attractive versus 5% Treasuries. However, Altria's minimal capex ($200M annually) and negative net debt position (-7.34 D/E ratio suggests cash exceeds debt) insulate operations from financing cost increases. Rate sensitivity is purely multiple compression risk, not operational impact.
minimal - Consumers purchase tobacco products with cash/debit regardless of credit conditions. No financing component to sales. Company maintains investment-grade credit rating with strong interest coverage from $9.3B operating cash flow.
dividend - Altria attracts income-focused investors seeking 7.5%+ dividend yield with quarterly payments, backed by $9.1B annual free cash flow. Value investors also participate given 5.4x P/S and 12.5x EV/EBITDA multiples trading below historical averages due to regulatory/secular concerns. Not suitable for ESG mandates or growth investors given declining volumes and sin stock classification.
low - Beta typically 0.6-0.8 reflecting defensive characteristics and yield support. Stock moves on regulatory headlines (FDA actions) and quarterly volume/pricing data, but 86.6% gross margins and predictable cash flows dampen volatility. Recent 25.4% one-year return reflects multiple expansion from rate cut expectations and dividend yield compression.
